Distribution of vascular endothelial growth factor (VEGF) in prostate disease.
Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimens. A positive result was indicated by area staining >25% and +2 or +3 staining intensity. Positive epithelial staining was observed in 50% of BPH specimens and 56% of cancer specimens, while positive stromal staining was observed in 73% of BPH specimens and 30% of cancer specimens. This may reflect an active role for stromal VEGF in the pathological process of BPH.
Walsh
K
K
Departments of Pathology and Urology, Kings College Hospital, London, UK. Kilian@globalnet.co.uk
Sriprasad
S
S
Hopster
D
D
Codd
J
J
Mulvin
D
D
D016228:Endothelial Growth Factors / Q000032:analysis* / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis* / Q000494:pharmacology; D008222:Lymphokines / Q000032:analysis* / Q000494:pharmacology; D008297:Male; D011470:Prostatic Hyperplasia / Q000473:pathology* / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors